TP53 and cancer: Indeed, somatic mutations as in oncogene (KRAS) and onco-suppressor genes (TP53, CDKN2A, SMAD Family Member 4 SMAD4), that support cancer aggressiveness, are important for the diagnosis of this malignant phenotype [2,7].